MSL
ENTA icon

Mackay Shields LLC’s Enanta Pharmaceuticals ENTA Stock Holding History

Mackay Shields LLC’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-19,375
Closed -$887K – 1525
2020
Q3 		$887K Buy
19,375
+500
+3% +$24.2K 0.01% 1055
2020
Q2 		$947K Sell
18,875
-4,400
-19% -$228K 0.01% 1039
2020
Q1 		$1.2M Buy
23,275
+5,300
+29% +$282K 0.01% 885
2019
Q4 		$1.11M Sell
17,975
-2,800
-13% -$174K 0.01% 1046
2019
Q3 		$1.25M Buy
20,775
+2,800
+16% +$208K 0.01% 1062
2019
Q2 		$1.52M Buy
17,975
+11,183
+165% +$1.01M 0.01% 1006
2019
Q1 		$649K Hold
6,792
– – ﹤0.01% 1118
2018
Q4 		$481K Buy
6,792
+292
+4% +$22.4K ﹤0.01% 1152
2018
Q3 		$555K Buy
+6,500
New +$651K ﹤0.01% 988

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Mackay Shields LLC's ENTA Position: Q4 2020 in Review

Mackay Shields LLC sold out of Enanta Pharmaceuticals (ENTA) in Q4 2020, closing a stake of 19,375 shares — an estimated $887K sold.

Mackay Shields LLC first reported a position in ENTA in Q3 2018 and held it in 9 quarters. The position peaked at $1.52M in Q2 2019. 151 funds tracked by Wall St. Rank hold ENTA as of Q4 2020.

  • Mackay Shields LLC reported no remaining Enanta Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Mackay Shields LLC sold 19,375 Enanta Pharmaceuticals shares in Q4 2020, an estimated $887K.
  • Mackay Shields LLC first reported a position in Enanta Pharmaceuticals in Q3 2018 and held it in 9 quarters.
  • Mackay Shields LLC's Enanta Pharmaceuticals position peaked at $1.52M in Q2 2019.
  • 151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2020.

Based on Mackay Shields LLC's 13F filing for Q4 2020, filed 16 Feb 2021.